1. Home
  2. FATE vs HEQ Comparison

FATE vs HEQ Comparison

Compare FATE & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

HOLD

Current Price

$1.93

Market Cap

125.6M

Sector

Health Care

ML Signal

HOLD

HEQ

John Hancock Hedged Equity & Income Fund of Beneficial Interest

SELL

Current Price

$11.33

Market Cap

139.0M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
FATE
HEQ
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
139.0M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
FATE
HEQ
Price
$1.93
$11.33
Analyst Decision
Buy
Analyst Count
11
0
Target Price
★ $5.74
N/A
AVG Volume (30 Days)
★ 1.6M
25.0K
Earning Date
11-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
★ 29.88
N/A
EPS
N/A
★ N/A
Revenue
★ $6,646,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.95
$10.50
52 Week High
$3.23
$12.00

Technical Indicators

Market Signals
Indicator
FATE
HEQ
Relative Strength Index (RSI) 28.79 52.00
Support Level $1.81 $11.27
Resistance Level $2.60 $11.63
Average True Range (ATR) 0.13 0.19
MACD -0.04 0.03
Stochastic Oscillator 5.11 86.36

Price Performance

Historical Comparison
FATE
HEQ

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest

John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.

Share on Social Networks: